Madeleine Carreau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Madeleine Carreau has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Manuel Buchwald
From the Unité de génétique humaine et moléculaire, CHUQ-Hôpital St-François d'Assise, Québec, QC, Canada; the Department of Pediatrics, Laval University, Québec, QC, Canada; the Program in Genetic and Genomic Biology and the Program in Cancer/Blood Research, Research Institute, Hospital for Sick Children, Toronto, ON, Canada; and the Department of Molecular and Medical Genetics and Pediatrics, University of Toronto, Toronto, ON, Canada
4 shared publicationsAndrea Bacigalupo
1 shared publication- André Tichelli
Division of Hematology, University Hospital Basel, Basel, Switzerland
1 shared publication - Anna Locasciulli
Ematologia Pediatrica e Trapianto di Midollo, Ospedale San Camillo, Roma, Italy
1 shared publication Aruna Raghavachar
1 shared publicationBlanche P. Alter
1 shared publication
Latest Publications
- 3 March 2007
- Published by Springer Nature
- p. 92-102
Therapy for Fanconi Anemia
- 1 September 2005
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 23 (8) , 1135-1141
Lack of Self‐Renewal Capacity in Fancc −/− Stem Cells After Ex Vivo Expansion
Treatments of the hematological manifestation in Fanconi anemia (FA) are first supported by attempts to stimulate hematopoiesis with androgens or hematopoietic growth factors. However, the long-term curative treatment of the hematological manifestation in FA patients is bone marrow (BM) or cord blood stem cell transplantation. The success rate for BM transplantation is fairly high with HLA-matched sibling donors but is, unfortunately, low with HLA-matched unrelated donors. An alternative curative treatment for those patients with no sibling donors might be gene transfer into hematopoietic stem cells. Because FA patients have reduced numbers of stem/progenitor cells, ex vivo expansion of hematopoietic stem cells would be a crucial step in gene transfer protocols. Using the FA mouse model, Fancc-/-, we tested the ability of CD34- hematopoietic stem cells to support ex vivo expansion. We determined that Fancc-/- CD34- stem cells have reduced reconstitution ability and markedly reduced self-renewal ability after culture, as shown by secondary transplants. These results indicate that FA stem cells may not be well suited for ex vivo expansion before gene transfer or transplantation protocols.
- 1 September 2005
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 23 (8) , 1135-1141
Lack of Self‐Renewal Capacity in Fancc −/− Stem Cells After Ex Vivo Expansion
Treatments of the hematological manifestation in Fanconi anemia (FA) are first supported by attempts to stimulate hematopoiesis with androgens or hematopoietic growth factors. However, the long-term curative treatment of the hematological manifestation in FA patients is bone marrow (BM) or cord blood stem cell transplantation. The success rate for BM transplantation is fairly high with HLA-matched sibling donors but is, unfortunately, low with HLA-matched unrelated donors. An alternative curative treatment for those patients with no sibling donors might be gene transfer into hematopoietic stem cells. Because FA patients have reduced numbers of stem/progenitor cells, ex vivo expansion of hematopoietic stem cells would be a crucial step in gene transfer protocols. Using the FA mouse model, Fancc-/-, we tested the ability of CD34- hematopoietic stem cells to support ex vivo expansion. We determined that Fancc-/- CD34- stem cells have reduced reconstitution ability and markedly reduced self-renewal ability after culture, as shown by secondary transplants. These results indicate that FA stem cells may not be well suited for ex vivo expansion before gene transfer or transplantation protocols.
- Open Access
- 16 June 2003
- Published by Springer Nature in BMC Hematology
- Vol. 3 (1) , 1
Fanconi anemia genes are highly expressed in primitive CD34+hematopoietic cells
- 16 June 2003
- Published by Springer Nature in BMC Hematology
- Vol. 3 (1) , 1
Open AccessFanconi anemia genes are highly expressed in primitive CD34+hematopoietic cells
- 1 September 2002
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 20 (5) , 438-447
Hematopoietic Stem Cells from Fancc −/− Mice Have Lower Growth and Differentiation Potential in Response to Growth Factors
Fanconi anemia (FA) is a complex recessive genetic disease characterized by progressive bone marrow (BM) failure. We have previously shown that stem cells from the FA group C mouse model have lower long-term primary and secondary reconstitution ability, and that bone marrow of Fancc(-/-) mice contained fewer lineage-negative (Lin(-))Thy1.2(low)Sca-1(+)c-kit(+) CD34(+) cells but normal levels of Lin(-)Thy1.2(low)Sca-1(+)c-kit(+)CD34(-) primitive cells. These data suggest that CD34(+) primitive cells have either a lower growth or differentiation potential, or that these cells have greater apoptosis levels. To investigate the role Fancc might have on the growth and differentiation potentials of primitive hematopoietic stem cells, we used a single-cell culture system and monitored cell viability, doubling potential, and apoptosis levels of Fancc(-/-) primitive Lin(-)Thy1.2(-)Sca-1(+) (LTS)-CD34(+) and LTS-CD34(-) stem cells. Results showed that Fancc(-/-) LTS-CD34(-) and LTS-CD34(+) cells had altered growth and apoptosis responses to combinations of stimulatory cytokines, most dramatically in response to a combination of factors that included interleukin-3 (IL-3) and IL-6. In addition, Fancc(-/-) LTS-CD34(-) and LTS-CD34(+) cells showed a lower differentiation potential than Fancc(+/+) cells. These results support a role for Fancc in the growth and differentiation of primitive hematopoietic cells and suggest that an altered response to stimulatory cytokines may contribute to BM aplasia in FA patients.
- 1 September 2002
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 20 (5) , 438-447
Hematopoietic Stem Cells from Fancc −/− Mice Have Lower Growth and Differentiation Potential in Response to Growth Factors
Fanconi anemia (FA) is a complex recessive genetic disease characterized by progressive bone marrow (BM) failure. We have previously shown that stem cells from the FA group C mouse model have lower long-term primary and secondary reconstitution ability, and that bone marrow of Fancc(-/-) mice contained fewer lineage-negative (Lin(-))Thy1.2(low)Sca-1(+)c-kit(+) CD34(+) cells but normal levels of Lin(-)Thy1.2(low)Sca-1(+)c-kit(+)CD34(-) primitive cells. These data suggest that CD34(+) primitive cells have either a lower growth or differentiation potential, or that these cells have greater apoptosis levels. To investigate the role Fancc might have on the growth and differentiation potentials of primitive hematopoietic stem cells, we used a single-cell culture system and monitored cell viability, doubling potential, and apoptosis levels of Fancc(-/-) primitive Lin(-)Thy1.2(-)Sca-1(+) (LTS)-CD34(+) and LTS-CD34(-) stem cells. Results showed that Fancc(-/-) LTS-CD34(-) and LTS-CD34(+) cells had altered growth and apoptosis responses to combinations of stimulatory cytokines, most dramatically in response to a combination of factors that included interleukin-3 (IL-3) and IL-6. In addition, Fancc(-/-) LTS-CD34(-) and LTS-CD34(+) cells showed a lower differentiation potential than Fancc(+/+) cells. These results support a role for Fancc in the growth and differentiation of primitive hematopoietic cells and suggest that an altered response to stimulatory cytokines may contribute to BM aplasia in FA patients.
- Open Access
- 15 August 2002
- Published by American Society of Hematology in Blood
- Vol. 100 (4) , 1499-1501
Short-term granulocyte colony-stimulating factor and erythropoietin treatment enhances hematopoiesis and survival in the mitomycin C–conditioned Fancc−/− mouse model, while long-term treatment is ineffective
Transient treatment with cytokines appears to improve hematopoietic function in Fanconi anemia; however, the effectiveness or adverse effect of long-term treatment is not known. The mitomycin C–treatedFancc −/− mouse provides a valuable model to address long-term efficacy of such treatment.Fancc −/− mice injected with granulocyte colony-stimulating factor, erythropoietin, or both cytokines showed a delay in mitomycin C (MMC)–induced bone marrow (BM) failure compared to untreated mice. However, long-term cytokine exposure followed by MMC challenges did not protect mice from the reduction of peripheral blood counts or the number of early myeloid progenitors. These results suggest that cytokine treatment may be beneficial only in the short-term, while long-term treatment is not protective for BM aplasia.
- 15 August 2002
- Published by American Society of Hematology in Blood
- Vol. 100 (4) , 1499-1501
Open AccessShort-term granulocyte colony-stimulating factor and erythropoietin treatment enhances hematopoiesis and survival in the mitomycin C–conditioned Fancc−/− mouse model, while long-term treatment is ineffective
Transient treatment with cytokines appears to improve hematopoietic function in Fanconi anemia; however, the effectiveness or adverse effect of long-term treatment is not known. The mitomycin C–treatedFancc −/− mouse provides a valuable model to address long-term efficacy of such treatment.Fancc −/− mice injected with granulocyte colony-stimulating factor, erythropoietin, or both cytokines showed a delay in mitomycin C (MMC)–induced bone marrow (BM) failure compared to untreated mice. However, long-term cytokine exposure followed by MMC challenges did not protect mice from the reduction of peripheral blood counts or the number of early myeloid progenitors. These results suggest that cytokine treatment may be beneficial only in the short-term, while long-term treatment is not protective for BM aplasia.
- 11 November 1999
- Published by Cambridge University Press (CUP)
- p. 338-354
Genetic basis of Fanconi's anemia
- 11 November 1999
- Published by Cambridge University Press (CUP)
- p. 338-354
Genetic basis of Fanconi's anemia
- 11 November 1999
- Published by Cambridge University Press (CUP)
Aplastic Anemia
This book takes account of the most recent findings in laboratory research and clinical trials to provide a comprehensive and up-to-date reference on the pathophysiology, epidemiology, diagnosis and treatment of acquired and inherited aplastic anemia. As well as a detailed overview of the pathophysiology of the disease, the international team of authors cover all aspects of management, including the established approaches of bone marrow transplantation and immunosuppressive treatment, new approaches such as the use of hematopoietic growth factors and escalated immunosuppression, and controversial issues such as stem cell transplantation. Also included is an important international consensus document on treatment, and a final section concentrates on the inherited syndrome Fanconi's anemia. Detailed treatment guidelines are given, making this the definitive resource for hematologists and other clinicians involved in the management and supportive care of patients with aplastic anemia. Scientists interested in bone marrow failure will also find this an invaluable reference.
- 11 November 1999
- Published by Cambridge University Press (CUP)
Aplastic Anemia
This book takes account of the most recent findings in laboratory research and clinical trials to provide a comprehensive and up-to-date reference on the pathophysiology, epidemiology, diagnosis and treatment of acquired and inherited aplastic anemia. As well as a detailed overview of the pathophysiology of the disease, the international team of authors cover all aspects of management, including the established approaches of bone marrow transplantation and immunosuppressive treatment, new approaches such as the use of hematopoietic growth factors and escalated immunosuppression, and controversial issues such as stem cell transplantation. Also included is an important international consensus document on treatment, and a final section concentrates on the inherited syndrome Fanconi's anemia. Detailed treatment guidelines are given, making this the definitive resource for hematologists and other clinicians involved in the management and supportive care of patients with aplastic anemia. Scientists interested in bone marrow failure will also find this an invaluable reference.
- 1 April 1999
- Published by Springer Nature in Pediatric Research
- Vol. 45 (4, Part 2 ) , 147A
Loss of FancC Function Results in Decreased Hematopoietic Stem Cell Repopulating Ability
- 1 April 1999
- Published by Springer Nature in Pediatric Research
- Vol. 45 (4, Part 2 ) , 147A
Loss of FancC Function Results in Decreased Hematopoietic Stem Cell Repopulating Ability